Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.03
OTCPK:TEVJF's Cash-to-Debt is ranked lower than
97% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. OTCPK:TEVJF: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:TEVJF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.3 Max: 1.03
Current: 0.03
0.03
1.03
Equity-to-Asset 0.36
OTCPK:TEVJF's Equity-to-Asset is ranked lower than
84% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OTCPK:TEVJF: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:TEVJF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.5 Max: 0.59
Current: 0.36
0.36
0.59
Interest Coverage 3.90
OTCPK:TEVJF's Interest Coverage is ranked lower than
84% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. OTCPK:TEVJF: 3.90 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:TEVJF' s Interest Coverage Range Over the Past 10 Years
Min: 3.6  Med: 11.95 Max: 19.16
Current: 3.9
3.6
19.16
Piotroski F-Score: 3
Altman Z-Score: 0.84
Beneish M-Score: -2.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 9.70
OTCPK:TEVJF's Operating Margin % is ranked higher than
54% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. OTCPK:TEVJF: 9.70 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:TEVJF' s Operating Margin % Range Over the Past 10 Years
Min: 8.12  Med: 17.02 Max: 25.46
Current: 9.7
8.12
25.46
Net Margin % 1.29
OTCPK:TEVJF's Net Margin % is ranked lower than
67% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. OTCPK:TEVJF: 1.29 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:TEVJF' s Net Margin % Range Over the Past 10 Years
Min: 1.29  Med: 12.03 Max: 20.75
Current: 1.29
1.29
20.75
ROE % 0.07
OTCPK:TEVJF's ROE % is ranked lower than
68% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. OTCPK:TEVJF: 0.07 )
Ranked among companies with meaningful ROE % only.
OTCPK:TEVJF' s ROE % Range Over the Past 10 Years
Min: 0.07  Med: 9.71 Max: 15.72
Current: 0.07
0.07
15.72
ROA % 0.39
OTCPK:TEVJF's ROA % is ranked lower than
66% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. OTCPK:TEVJF: 0.39 )
Ranked among companies with meaningful ROA % only.
OTCPK:TEVJF' s ROA % Range Over the Past 10 Years
Min: 0.39  Med: 4.81 Max: 9.07
Current: 0.39
0.39
9.07
ROC (Joel Greenblatt) % 17.61
OTCPK:TEVJF's ROC (Joel Greenblatt) % is ranked higher than
58% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. OTCPK:TEVJF: 17.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:TEVJF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.82  Med: 32.53 Max: 48.06
Current: 17.61
16.82
48.06
3-Year Revenue Growth Rate 2.90
OTCPK:TEVJF's 3-Year Revenue Growth Rate is ranked lower than
71% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. OTCPK:TEVJF: 2.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:TEVJF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.8  Med: 9.5 Max: 26.6
Current: 2.9
1.8
26.6
3-Year EBITDA Growth Rate -3.90
OTCPK:TEVJF's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. OTCPK:TEVJF: -3.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:TEVJF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -12  Med: 11.6 Max: 47.1
Current: -3.9
-12
47.1
3-Year EPS without NRI Growth Rate -62.30
OTCPK:TEVJF's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. OTCPK:TEVJF: -62.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:TEVJF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -62.3  Med: 9.4 Max: 67.9
Current: -62.3
-62.3
67.9
GuruFocus has detected 6 Warning Signs with Teva Pharmaceutical Industries Ltd $OTCPK:TEVJF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:TEVJF's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF640.2511.187 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:TKPYY, NYSE:ZTS, NAS:MYL, OTCPK:SGIOF, OTCPK:ESALY, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, OTCPK:APNHY, OTCPK:SFOSF, OTCPK:HLUYY, NYSE:RDY, OTCPK:IPSEY, OTCPK:HKMPY, NYSE:MNK, NYSE:VRX, OTCPK:HYPMY, NAS:OPK, NYSE:TARO, NYSE:PTHN » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVA.USA,
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.

Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments generic and specialty medicines. The generics segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients ("API"). The specialty segment engages in the development, manufacture, sale and distribution of branded specialty medicines such as those for central nervous system and respiratory indications, as well as those marketed in the women's health, oncology and other specialty businesses. Its other activities include the over-the-counter ("OTC") medicines business, distribution activity mainly in Israel and Hungary and medical devices. The OTC activity is mainly conducted through a joint venture with P&G, which combines Company's production capabilities and market reach with P&G's marketing expertise and expansive platform. It has market presence in the United States, Europe and other markets. The Generic medicines include chemical and therapeutic equivalents of originator medicines in dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty medicines include several franchises in the core therapeutic areas of CNS medicines such as Copaxone, Azilect, Nuvigil and Zecuity and of respiratory medicines such as ProAir HFA and QVAR. It also includes other therapeutic areas, such as oncology medicines, including Treanda, women's health and selected other areas. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").

Ratios

vs
industry
vs
history
PE Ratio 3775.00
TEVJF's PE Ratio is ranked lower than
99% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.40 vs. TEVJF: 3775.00 )
Ranked among companies with meaningful PE Ratio only.
TEVJF' s PE Ratio Range Over the Past 10 Years
Min: 16.72  Med: 29.69 Max: 3775
Current: 3775
16.72
3775
Forward PE Ratio 7.74
TEVJF's Forward PE Ratio is ranked higher than
91% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. TEVJF: 7.74 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 3775.00
TEVJF's PE Ratio without NRI is ranked lower than
99% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.84 vs. TEVJF: 3775.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
TEVJF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 16.72  Med: 29.69 Max: 3775
Current: 3775
16.72
3775
Price-to-Owner-Earnings 16.39
TEVJF's Price-to-Owner-Earnings is ranked higher than
81% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.72 vs. TEVJF: 16.39 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TEVJF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.14  Med: 14.96 Max: 23.02
Current: 16.39
10.14
23.02
PB Ratio 1.26
TEVJF's PB Ratio is ranked higher than
84% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. TEVJF: 1.26 )
Ranked among companies with meaningful PB Ratio only.
TEVJF' s PB Ratio Range Over the Past 10 Years
Min: 1.15  Med: 2.05 Max: 2.74
Current: 1.26
1.15
2.74
PS Ratio 1.65
TEVJF's PS Ratio is ranked higher than
75% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. TEVJF: 1.65 )
Ranked among companies with meaningful PS Ratio only.
TEVJF' s PS Ratio Range Over the Past 10 Years
Min: 1.51  Med: 2.57 Max: 3.08
Current: 1.65
1.51
3.08
Price-to-Free-Cash-Flow 8.39
TEVJF's Price-to-Free-Cash-Flow is ranked higher than
89% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.72 vs. TEVJF: 8.39 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TEVJF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.66  Med: 10.98 Max: 12.08
Current: 8.39
7.66
12.08
Price-to-Operating-Cash-Flow 6.94
TEVJF's Price-to-Operating-Cash-Flow is ranked higher than
86% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. TEVJF: 6.94 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TEVJF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.34  Med: 9.38 Max: 10.33
Current: 6.94
6.34
10.33
EV-to-EBIT 60.97
TEVJF's EV-to-EBIT is ranked lower than
86% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.65 vs. TEVJF: 60.97 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVJF' s EV-to-EBIT Range Over the Past 10 Years
Min: 18.4  Med: 35.4 Max: 213.6
Current: 60.97
18.4
213.6
EV-to-EBITDA 28.30
TEVJF's EV-to-EBITDA is ranked lower than
70% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. TEVJF: 28.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVJF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.9  Med: 19.8 Max: 40.6
Current: 28.3
12.9
40.6
Shiller PE Ratio 16.64
TEVJF's Shiller PE Ratio is ranked higher than
90% of the 158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 47.37 vs. TEVJF: 16.64 )
Ranked among companies with meaningful Shiller PE Ratio only.
TEVJF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.18  Med: 23.64 Max: 29.18
Current: 16.64
15.18
29.18
Current Ratio 0.92
TEVJF's Current Ratio is ranked lower than
88% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. TEVJF: 0.92 )
Ranked among companies with meaningful Current Ratio only.
TEVJF' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.59 Max: 2.95
Current: 0.92
0.92
2.95
Quick Ratio 0.65
TEVJF's Quick Ratio is ranked lower than
88% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. TEVJF: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
TEVJF' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 1.08 Max: 2.18
Current: 0.65
0.65
2.18
Days Inventory 161.00
TEVJF's Days Inventory is ranked lower than
72% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. TEVJF: 161.00 )
Ranked among companies with meaningful Days Inventory only.
TEVJF' s Days Inventory Range Over the Past 10 Years
Min: 160.36  Med: 189.42 Max: 208.13
Current: 161
160.36
208.13
Days Sales Outstanding 129.38
TEVJF's Days Sales Outstanding is ranked lower than
79% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. TEVJF: 129.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVJF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 129.38
95.91
153.21
Days Payable 80.85
TEVJF's Days Payable is ranked higher than
56% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. TEVJF: 80.85 )
Ranked among companies with meaningful Days Payable only.
TEVJF' s Days Payable Range Over the Past 10 Years
Min: 78.39  Med: 84.39 Max: 111.41
Current: 80.85
78.39
111.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.79
TEVJF's Dividend Yield % is ranked higher than
89% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. TEVJF: 3.79 )
Ranked among companies with meaningful Dividend Yield % only.
TEVJF' s Dividend Yield % Range Over the Past 10 Years
Min: 1.85  Med: 2.27 Max: 3.89
Current: 3.79
1.85
3.89
Dividend Payout Ratio 19.43
TEVJF's Dividend Payout Ratio is ranked lower than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.36 vs. TEVJF: 19.43 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TEVJF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.31 Max: 19.43
Current: 19.43
0.12
19.43
3-Year Dividend Growth Rate 17.30
TEVJF's 3-Year Dividend Growth Rate is ranked lower than
65% of the 285 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.10 vs. TEVJF: 17.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TEVJF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -19.3  Med: 6.4 Max: 46.9
Current: 17.3
-19.3
46.9
Forward Dividend Yield % 3.79
TEVJF's Forward Dividend Yield % is ranked higher than
87% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. TEVJF: 3.79 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 12.57
TEVJF's 5-Year Yield-on-Cost % is ranked higher than
90% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. TEVJF: 12.57 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TEVJF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 6.14  Med: 7.53 Max: 12.9
Current: 12.57
6.14
12.9
3-Year Average Share Buyback Ratio -2.30
TEVJF's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. TEVJF: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVJF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -2.3 Max: 1.2
Current: -2.3
-12.6
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.55
TEVJF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. TEVJF: 0.55 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TEVJF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 0.93 Max: 1.07
Current: 0.55
0.55
1.07
Price-to-Median-PS-Value 0.56
TEVJF's Price-to-Median-PS-Value is ranked higher than
90% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. TEVJF: 0.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEVJF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 0.98 Max: 1.05
Current: 0.56
0.56
1.05
Earnings Yield (Greenblatt) % 1.60
TEVJF's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. TEVJF: 1.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEVJF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 2.8 Max: 5.4
Current: 1.6
0.5
5.4
Forward Rate of Return (Yacktman) % 7.44
TEVJF's Forward Rate of Return (Yacktman) % is ranked lower than
53% of the 358 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.67 vs. TEVJF: 7.44 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TEVJF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -4.1  Med: 1.2 Max: 8.7
Current: 7.44
-4.1
8.7

More Statistics

Revenue (TTM) (Mil) $21,903
EPS (TTM) $ 0.06
Beta-0.28
Short Percentage of Float0.00%
52-Week Range $35.90 - 60.76
Shares Outstanding (Mil)1,014.99

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 23,421 23,606 24,088
EPS ($) 4.79 4.75 5.09
EPS without NRI ($) 4.79 4.75 5.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-0.37%
Dividends per Share ($) 1.36 1.50 1.65
» More Articles for OTCPK:TEVJF

Headlines

Articles On GuruFocus.com
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017 
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
John Paulson's Bargain Stock Jan 30 2017 
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
4 Stocks Reach Their 3-Year Low Prices Dec 31 2016 
10 for 2017! Investment Picks for the New Year Dec 23 2016 
Teva Is a Hold Nov 30 2016 
Buy Health Care Now? It All Depends on the Election Nov 07 2016 

More From Other Websites
[$$] Israel has high hopes for its nascent medical marijuana sector Feb 16 2017
Blue Chips Dominate Jefferies Value Stocks to Buy Jun 23 2016
Impax Buys Mystery Generics Portfolio From Teva, Allergan Jun 21 2016
Impax Buying Teva, Allergan Drugs, Clearing Way For Deal Closing Jun 21 2016
Impax (IPXL) Stock Tumbles on Teva, Allergan Generic Drug Deal Jun 21 2016
Why CarMax, Teva Pharmaceuticals And Three Other Stocks Are in Spotlight on Tuesday Jun 21 2016
With Acquisitions, Will Impax Become the Next Great Generic Drug Seller? Jun 21 2016
Eagle Pharma Downgraded On 'Challenging' Hospital Environment Jun 20 2016
Weekly Biotech Report Covering Epizyme Inc (EPZM) Tazemetostat & Teva Pharamceutical Industries Ltd.... Jun 20 2016
Teva's Suspension of Marketing for Zecuity Product is Likely to Have Little Impact Jun 15 2016
Mesoblast shares tank after Teva exit Jun 14 2016
Mesoblast shares drop on outlook concerns Jun 13 2016
Mesoblast regains full rights to stem cell heart failure treatment Jun 13 2016
Allergan (AGN) Stock Advances After Dr. Reddy's Deal Jun 13 2016
Here’s Why These Five Stocks Are In the Spotlight Jun 13 2016
Dr. Reddy’s to Buy Generics From Allergan, Teva for $350 Million Jun 11 2016
Dr. Reddy’s to acquire product portfolio from TEVA for US Market Jun 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)